• Local control as assessed by MRI at 3 years [ Designated as safety issue: No ]
  

• Toxicity as assessed by CTC 2.0 [ Designated as safety issue: Yes ]
  
• Response as assessed by MRI [ Designated as safety issue: No ]
  

OBJECTIVES:

• Determine the efficacy of moderate-dose radiotherapy, in terms of local control, in patients with aggressive fibromatoses.
• Determine the acute and late side-effects of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive radiotherapy 5 days a week for 5.5 weeks for a total of 56 Gy in 28 fractions.

Patients are followed every 3 months for 2 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 3 years.

DISEASE CHARACTERISTICS:

• Histologically confirmed aggressive fibromatoses arising in any site

  • Primary, recurrent, or progressive disease that is inoperable or requires a major operation resulting in a large functional or cosmetic deficit or mutilation

    • Progressive disease defined as at least 20% increase in tumor size on 2 MRI scans within 1 year after any prior therapy except radiotherapy OR

  • Incompletely resected tumor with gross residual disease not suitable for further surgery

    • Resected within the past 3 months

• Lesions must be suitable for radiotherapy

  • No bulky intra-abdominal disease in close relation to small bowel
• Measurable disease

PATIENT CHARACTERISTICS:

Age:

• 16 and over

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Not specified

Renal:

• Not specified

Other:

• No conditions that would preclude study follow-up

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• Prior chemotherapy allowed
• No concurrent chemotherapy

Endocrine therapy:

• Prior endocrine therapy allowed
• No concurrent endocrine therapy

Radiotherapy:

• See Disease Characteristics
• No prior radiotherapy to indicator lesion

Surgery:

• See Disease Characteristics
• Prior surgery allowed

Other:

• No prior isolated limb perfusion with tumor necrosis factor
• No concurrent isolated limb perfusion with tumor necrosis factor